Xilio Therapeutics Inc (XLO) — Institutional Holders Breakdown (Q2 2026)

XLO ranks #7810 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

26 institutions disclose a position in XLO, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 1.0% of its own portfolio to it.

XLO is up 1.3% today, and institutions have been net buyers of $9.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

XLO reported a net loss of $21.8M over the trailing twelve months.

• Not yet profitable — net loss of $21.8M over the trailing twelve months
• Revenue grew 327.3% year over year
• Net income improved year over year, from -$56.2M to -$21.8M
• Operating cash flow was negative, using $5.0M in cash
• Current ratio of 2.58x — enough short-term assets to cover short-term liabilities
• Liabilities run 3.39x equity — a highly leveraged balance sheet worth noting